Sphingosine-1-phosphate (S1P) receptor modulators
Siponimod
The FDA lists this product in 12 strengths and forms.
Composition
- Active ingredients
- SIPONIMOD 1MG
Strengths and forms
The FDA lists each strength of a product separately; these pages share one label.
- SIPONIMOD 2MG · TabletANDA218228-003 · Tentative approval
- SIPONIMOD 0.25MG · TabletANDA218228-001 · Tentative approval
- SIPONIMOD 1MG · TabletThis page
- SIPONIMOD EQ 2MG BASE · TabletANDA218444-003 · Discontinued
- SIPONIMOD EQ 0.25MG BASE · TabletANDA218444-001 · Discontinued
- SIPONIMOD EQ 1MG BASE · TabletANDA218444-002 · Discontinued
- SIPONIMOD 1MG · TabletANDA218393-003 · Tentative approval
- SIPONIMOD 0.25MG · TabletANDA218393-001 · Tentative approval
- SIPONIMOD 2MG · TabletANDA218393-002 · Tentative approval
- SIPONIMOD EQ 2MG BASE · TabletANDA218459-003 · Discontinued
- SIPONIMOD EQ 0.25MG BASE · TabletANDA218459-001 · Discontinued
- SIPONIMOD EQ 1MG BASE · TabletANDA218459-002 · Discontinued
Official product information
Drugs@FDA lists the approved labels, letters and reviews for application ANDA218228.
At a glance
- Brand name
- Siponimod
- Drug class
- Sphingosine-1-phosphate (S1P) receptor modulators
- Route
- Oral
- Dosage form
- Tablet
- Applicant
- Cipla LTD
- Status
- Tentative approval
- FDA approval
- 10 Jan 2025
- Application
- ANDA218228-002
- RxCUI
- 2121085